These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 1894021)

  • 1. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
    Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
    Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM; Nestor JJ; Vickery BH
    Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women.
    Roseff SJ; Kettel LM; Rivier J; Burger HG; Baulieu E; Yen SS
    Fertil Steril; 1990 Nov; 54(5):805-10. PubMed ID: 2226914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation.
    Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
    Fertil Steril; 1991 Nov; 56(5):923-7. PubMed ID: 1936328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of luteinizing hormone in the control of inhibin and progesterone secretion by the human corpus luteum.
    McLachlan RI; Cohen NL; Vale WW; Rivier JE; Burger HG; Bremner WJ; Soules MR
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1078-85. PubMed ID: 2498381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable tolerance of the developing follicle and corpus luteum to gonadotropin-releasing hormone antagonist-induced gonadotropin withdrawal in the human.
    Hall JE; Bhatta N; Adams JM; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1991 May; 72(5):993-1000. PubMed ID: 1902489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteolysis induced by a luteinizing hormone-releasing hormone agonist is prevented by human chorionic gonadotropin.
    Bergquist C; Nillius SJ; Wide L
    Contraception; 1980 Oct; 22(4):341-7. PubMed ID: 7004772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience.
    Paulson RJ; Sauer MV; Lobo RA
    J Assist Reprod Genet; 1994 Jan; 11(1):28-32. PubMed ID: 7949832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The steroidogenic response and corpus luteum expression of the steroidogenic acute regulatory protein after human chorionic gonadotropin administration at different times in the human luteal phase.
    Kohen P; Castro O; Palomino A; Muñoz A; Christenson LK; Sierralta W; Carvallo P; Strauss JF; Devoto L
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3421-30. PubMed ID: 12843197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal LHRH agonist (Buserelin) after ovulation: a post-coital contraceptive approach.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Contracept Deliv Syst; 1983 Apr; 4(2):107-25. PubMed ID: 12338631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous luteinizing hormone surges can be reliably prevented by the timely administration of a gonadotrophin releasing hormone antagonist (Nal-Glu) during the late follicular phase.
    Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
    Hum Reprod; 1992 Aug; 7(7):930-3. PubMed ID: 1430131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
    Croxatto HB; Salvatierra AM; Croxatto HD; Spitz IM
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH.
    Dubourdieu S; Charbonnel B; D'Acremont MF; Carreau S; Spitz IM; Bouchard P
    J Clin Endocrinol Metab; 1994 Feb; 78(2):343-7. PubMed ID: 8106622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists.
    Hall JE; Whitcomb RW; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1990 Feb; 70(2):328-35. PubMed ID: 2105329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the luteolytic action of gonadotrophin-releasing hormone antagonist and cloprostenol, and the ability of human chorionic gonadotrophin and melatonin to override their luteolytic effects in the marmoset monkey.
    Webley GE; Hodges JK; Given A; Hearn JP
    J Endocrinol; 1991 Jan; 128(1):121-9. PubMed ID: 1900320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN; Wakefield G; Schlechter NL; Lindner J; Souza KH; Kamilaris TC; Konidaris S; Rivier JE; Vale WW; Toglia M
    J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accessory corpus luteum induced by human chorionic gonadotropin on day 7 or days 7 and 13 of the estrous cycle affected follicular and luteal dynamics and luteolysis in lactating Holstein cows.
    Cunha TO; Statz LR; Domingues RR; Andrade JPN; Wiltbank MC; Martins JPN
    J Dairy Sci; 2022 Mar; 105(3):2631-2650. PubMed ID: 34955260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.